SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the Company’s Chairman and CEO, will present an overview of the Company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 1:20 PM EST.
Related news for (SABS)
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/21/25 09:00 AM
- Top Biotech Movers: Transformative Breakthroughs Fuel Investor Interest Across Neurology, Autoimmunity, and Advanced Materials
- MoBot alert highlights: NASDAQ: SABS, NASDAQ: HSDT, NASDAQ: AIRE, NASDAQ: IXHL, NASDAQ: GCTK (07/21/25 07:00 AM)